Days af­ter In­di­v­ior launch­es au­tho­rized Sub­ox­one gener­ic, My­lan of­fers its copy­cat; In crowd­ed CGRP mar­ket, Alder sub­mits BLA

→ Af­ter a pro­tract­ed court bat­tle in the Unit­ed States to thwart gener­ic com­pe­ti­tion of its block­buster opi­oid ad­dic­tion treat­ment Sub­ox­one ul­ti­mate­ly proved in vain …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER